If you’ve followed along with me for even a short time, then you already know that I have a tendency to make bold predictions.
Here’s the thing. I’m convinced – and I have the track record to prove it – that to consistently crush the market, you have to be willing to buck the in-crowd on Wall Street and in Washington.
For me, it’s all about innovation. I always say that the road to wealth is paved with tech, and that’s why I’m always excited about bold new sectors that mainstream big investors might still be cautious about. I expect that 2020 is going to be an outstanding year for Bitcoin and other cryptocurrencies. Along with that, I’m expecting big things from the legal cannabis sector in this coming year.
Medical marijuana is one of the biggest healthcare stories out there right now.
We know that cannabis is a godsend for cancer patients, who use it to control their nausea and increase their appetite following chemotherapy.
Researchers are proving every day that cannabis-based drugs are effective against extreme pain, epilepsy, multiple sclerosis, and other ailments.
Plus, because of marijuana’s effectiveness in the fight against pain, everyone from doctors to law enforcement leaders are looking to use weed to help end the ongoing – and devastating – opioid crisis.
All that means medical marijuana is also one of the best investment opportunities out there.
That’s why I’ve recommended GW Pharmaceuticals PLC (Nasdaq ADR: GWPH) to you again and again.
But when it comes to medical marijuana, there’s a big problem.
Marijuana is probably the least studied cash crop in the world.
Researchers working to discover and refine the medicinal properties of cannabis have been greatly hampered by the Drug Enforcement Agency’s (DEA) classification of the plant as a Schedule 1 drug. That means the federal government deems marijuana as having no accepted medical use, like meth or heroin.
That stance has cut down on the sort of well-funded research that’s needed to usher in the next round of cannabis-based wonder drugs.
But that doesn’t mean no research is happening. After all, GW Pharma and other biotech firms have produced a first round of weed-based drugs.
In fact, there’s a small but growing cottage industry of tiny startups focused on the genetic testing of cannabis to help those biotechs
Some marijuana analytics startups, like Steep Hill, are developing their own gene-sequencing systems – and that’s something very exciting I plan to tell you more about soon.
But most, including Medicinal Genomics, are using state-of-the-art gene-sequencing equipment from the company I want to tell you about today.
This dynamic industry leader is a pioneer in the genetic testing equipment field. And now it’s equipment is crucial for medical marijuana pioneers.
If you got in when I first recommended this stock just a few months ago, you’ve already made nearly 19%.
But thanks to the medical marijuana sector’s interest and several more catalysts I’ll tell you about below, it’s got a lot further to run.
I had a terrible head cold – but the message got through.
No, it was more than a message…
It was a revelation.
It was back in June, and I was on the floor of the Fourth Annual Cannabis Business Summit & Expo in Oakland, California. My head was fuzzy due to the combo of viral infection and strong cold medicine, but I knew the conversation I was in was important.
I was talking to Chet Billings, CEO of legal cannabis investing company Mentor Capital Inc., and he was trying to explain the importance of compliance in his business. He was talking about cannabis companies’ need to follow all state and local business regulations – and to track their compliance.
Billings told me that we’re now approaching an era when mergers and acquisitions among marijuana companies are starting to happen. And buyers will only go after smaller firms of the highest quality. If they don’t have their compliance in order, he said, those acquirers will keep on trolling for more attractive fish.
The stakes are high, Billings said, and a lot of smaller operators simply don’t have experience with government regulation or the manpower to pay it the attention it needs without tech software to do the heavy lifting.
I must have still looked confused, because then he put it to me in a way that I, as a lifelong movie fan, could understand: “It’s like in the 1980s and ’90s when video rental shops still proliferated the landscape.”
Eventually, Billings recalled, Blockbuster came along and bought up the best video stores in each town. HollywoodVideo picked up the second-best ones. And the dustiest, most unfriendly places got left alone – and went out of business.
“Why would you want a ratty, local dispensary that resembles an old video store?” Billings said. “One false key stroke is a permanent violation. You get enough of those noncompliance violations – and you lose your license… and any chance at being a success.”
That’s one of the reasons why I’ve frequently recommended Microsoft Corp. (Nasdaq: MSFT) as a “starter” pot stock. The tech giant has made a big commitment to developing legal marijuana compliance software tools for governments and businesses.
And it’s really just one of the many “lessons” I’ve learned while out on the trail this year that I’ve used to make some of my members a mint through investing in the right marijuana stocks.
Now I’m using those same lessons to bring you these five pot stock predictions for 2018. All five are catalysts that will really drive the marijuana market upward in the next year.
Even after stacking up a bunch of double-, triple- and even quadruple-digit gains over the last year and a quarter, many of my Roadmap to Marijuana Millions pot stocks still have plenty of gas left.
In fact, a few of my Canadian legal marijuana plays in particular been on fire for months now – and especially since Nov. 10.
That’s the day Canada’s Department of Finance presented its cannabis tax plan on. The Canadian government plans to add a $1-per-gram excise tax on cannabis products, or 10% of the sale price, whichever is higher. Plus, the tax plan reiterated Canada’s commitment to legalize marijuana by July 2018.
No wonder my readers’ “Fast Fortune” Canadian pot stocks jumped higher.
One of those stocks rose 15% the day that news broke… another soared 10% that day… another jumped 6.8%… and another picked up13%.
But today we’re talking about the one that gained 15% on Nov. 10. We’re focusing on that one because it’s gone on to soar 76% since then thanks to another catalyst entirely. And it’s gained an amazing 766% since I first alerted my readers to it back in September 2016.
Today, I’ll tell you about that stock – and the “second” catalyst that boosted its gains.
Plus, I’ve identified another “trigger” that’s going to boost pot stocks on Jan. 1.
I want you to get in on these stocks before that catalyst hits.
The legal cannabis sector is no longer the “Wild West”-style marketplace it was back in, say, 2013, but there’s still plenty of volatility compared with the placid broader markets.
Then again, that’s why the right pot stocks reward forward-thinking investors with triple- and quadruple-digit gains. In fact, there’s a bevy of micro- and small-cap companies, any one of which could be the next mega-cap blockbuster – the long-sought-after “Starbucks of weed” or “Facebook of pot.”
My Nova-X Report’s Roadmap to Marijuana Millions model portfolio is chock-full of that kind of stocks. Right now my paid-up members are sitting on gains of 915%… 520.6%… 442.7%… and five more triple-digit winners. If you’d like to find out how to take advantage of this green revolution and get in on gains like those, click here.
But I don’t want to leave anyone with the impression that the only way to make a killing on pot stocks is to buy small, volatile companies. The gains from my Scotts Miracle-Gro Co. (NYSE: SMG) and GW Pharmaceuticals PLC (Nasdaq: GWPH) recommendations prove that just isn’t the case.
Then there’s the company I want to tell you about today.
It isn’t likely to quadruple your money quickly, but you’ll likely smash the market with double- and even triple-digit gains, and it pays a dividend that puts you way out ahead of inflation and low interest rates, too.
They may call it “weed,” but commercial legal cannabis – the “good stuff” – is more like a pampered, pedigreed dog.
Every pot grower knows that lots of care, technique, and technology goes into the cultivation and feeding of marijuana plants. All that’s needed so those plants can flower and produce commercially and medically useful compounds – especially the psychoactive tetrahydrocannabinol-9 (THC) that relieves pain and nausea and gets recreational users high.
This is seriously labor- and tech-intensive stuff. It’s also the specialty of the company I’m going to show you today.